Abstract:Epilepsy is one of the most prevalent neurological disorders, affecting more than 45 million people worldwide. Recent advances in genetic techniques, such as next-generation sequencing, have driven genetic discovery and increased our understanding of the molecular and cellular mechanisms behind many epilepsy syndromes. These insights prompt the development of personalized therapies tailored to the genetic characteristics of an individual patient. However, the surging number of novel genetic variants renders the interpretation of pathogenetic consequences and of potential therapeutic implications ever more challenging. Model organisms can help explore these aspects in vivo . In the last decades, rodent models have significantly contributed to our understanding of genetic epilepsies but their establishment is laborious, expensive, and time-consuming. Additional model organisms to investigate disease variants on a large scale would be desirable. The fruit fly Drosophila melanogaster has been used as a model organism in epilepsy research since the discovery of "bang-sensitive" mutants more than half a century ago. These flies respond to mechanical stimulation, such as a brief vortex, with stereotypic seizures and paralysis. Furthermore, the identification of seizure-suppressor mutations allows to pinpoint novel therapeutic targets. Gene editing techniques, such as CRISPR/Cas9, are a convenient way to generate flies carrying disease-associated variants. These flies can be screened for phenotypic and behavioral abnormalities, shifting of seizure thresholds, and response to anti-seizure medications and other substances. Moreover, modification of neuronal activity and seizure induction can be achieved using optogenetic tools. In combination with calcium and fluorescent imaging, functional alterations caused by mutations in epilepsy genes can be traced. Here, we review Drosophila as a versatile model organism to study genetic epilepsies, especially as 81% of human epilepsy genes have an orthologous gene in Drosophila . Furthermore, we discuss newly established analysis techniques that might be used to further unravel the pathophysiological aspects of genetic epilepsies.

Functional analysis of epilepsy-associated GABAA receptor mutations using Caenorhabditis elegans

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action

Zebrafish models of candidate human epilepsy-associated genes provide evidence of hyperexcitability

Epileptic phenotypes in loss-of-function zebrafish are rescued by blocking NMDA receptor signaling

Modeling neurodegeneration in Caenorhabditis elegans

Plural molecular and cellular mechanisms of pore domain KCNQ2 encephalopathy

Rapid modeling of an ultra-rare epilepsy patient variant in mice by in utero prime editing

Functional analysis of the epilepsy gene Pcdh19 using a novel GFP-reporter mouse model

A unified genome constraint, pathogenicity, and pLoF model identifies new genes associated with epilepsy

Allele‐Specific Editing of a Dominant SCN8A Epilepsy Variant Protects against Seizures and Lethality in a Murine Model

Presynaptic hyperexcitability reversed by positive allosteric modulation of a GABABR epilepsy variant

Genetic modeling of GNAO1 disorder delineates mechanisms of Go dysfunction

Functional characterization of a KCNAB3 genetic epilepsy with febrile seizures plus adult mouse model

Drosophila melanogaster as a versatile model organism to study genetic epilepsies: An overview

Generation of two patient specific GABRD variants and their isogenic controls for modeling epilepsy

Pathogenicity Prediction of GABAA Receptor Missense Variants

A knock-in mouse model for KCNQ2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment

Genomic evidence for the suitability of Göttingen Minipigs with a rare seizure phenotype as a model for human epilepsy

De novo variants in GABRA2 and GABRA5 alter receptor function and contribute to early-onset epilepsy